Loading...
Sproutly Canada Inc.
SPR.CN•CNQ
Healthcare
Drug Manufacturers - Specialty & Generic
CA$0.02
CA$0.00(0.00%)

Over the last four quarters, Sproutly Canada Inc.'s revenue moved from $0.00 in Q3 2022 to $0.00 in Q2 2023. Operating income in Q2 2023 was $0.00, with a strong operating margin of N/A. Despite fluctuations in R&D and SG&A expenses, EBITDA for Sproutly Canada Inc. remained robust at $0.00, reflecting operational efficiency. Net income rose to $0.00, with an EPS of $0.00. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan